Tara Lynn Kieffer
Known title: Sr. VP, New Product Dev.CIK: 0001834835
Associated companies
Transaction History
| ENTA | ▲ Buy | Grant | 1,575 | $0 | 2/12/2026 | View on chart |
| ENTA | ▲ Buy | Grant | 4,987 | $0 | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 3,257 | $46K | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,106 | $30K | 12/5/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 753 | $11K | 12/1/2025 | View on chart |
| ENTA | ▲ Buy | Grant | 7,500 | $0 | 2/12/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 3,326 | $19K | 2/12/2025 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,283 | $18K | 12/6/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 753 | $6K | 12/1/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 7,266 | $90K | 6/17/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 973 | $12K | 2/12/2024 | View on chart |
| ENTA | ▲ Buy | Grant | 3,320 | $0 | 2/12/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,125 | $20K | 12/5/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 753 | $7K | 12/1/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 6,725 | $355K | 2/13/2023 | View on chart |
| ENTA | ▲ Buy | Grant | 11,747 | $0 | 2/13/2023 | View on chart |
| ENTA | ▲ Buy | Grant | 9,250 | $0 | 2/13/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 498 | $22K | 12/1/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 18,500 | $0 | 11/23/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 552 | $34K | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 327 | $0 | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 1,289 | $0 | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 6,800 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.